Impact of PCV on Disease and Colonization Among Native American Communities

Invasive Pneumococcal Disease Clinical Trial

Official title:

Impact of PCV on Disease and Colonization Among Native American Communities

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01083459
• Other study ID #: R01MD004011-01
• Status: Completed
• Phase: N/A
• First received: March 8, 2010
• Last updated: January 16, 2015
• Start date: January 2010
• Est. completion date: April 2012

Study information

• Verified date: January 2015
• Source: Johns Hopkins Bloomberg School of Public Health
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to determine the impact of pneumococcal conjugate vaccine on carriage of pneumococcus in the nasopharynx and on the incidence of invasive pneumococcal disease in the community.

Description:

Pneumococcus is a bacterium that healthy people commonly have in their nose and throat; this is called pneumococcal 'carriage'. Carriage is usually harmless, but can progress to serious disease like pneumonia, meningitis, and blood stream infections or to less serious, but burdensome, diseases like sinusitis or ear infections. Infants and the elderly bear the greatest burden of pneumococcal disease with over 800,000 annual global deaths from this germ among children under 5 years of age. Furthermore, pneumococcus has developed resistance to antibiotics making it increasingly difficult to treat pneumococcal infections. Within the United States some Native American groups, like the Navajo and the White Mountain Apache tribes, suffer from pneumococcal disease much more often than people in the general US population. We don't know why pneumococcus disproportionately afflicts these communities, but we know this health disparity can be significantly reduced through vaccination. In 2000, for the first time a pneumococcal vaccine designed specifically for infants, called PCV7, became available and was put into routine use among Navajo and Apache as well as the general US population. PCV7 contains the 7 most common of the >90 pneumococcal strains that exist. Although PCV7 is only given to infants and toddlers, it impacts pneumococcal disease throughout the community because it not only protects vaccinated infants from disease it also protects them against NP colonization. Infants and children are the main transmitters of pneumococcal colonization in the community so any change in their carriage affects the whole population of pneumococcal germs circulating within the family and community. Reductions in pneumococcal disease caused by the 7 types in PCV7 have exceeded expectations, especially among Navajo and Apache where we have seen virtually no cases in over 5 years. But, PCV7 has had the unintended consequence of increasing the amount of pneumococcal disease from some pneumococcal types that are not in PCV7. Therefore a new vaccine to protect against 13 pneumococcal strains, called PCV13, has been developed and is about to be licensed and used (expected licensure Q4/2009). This project aims to reveal the impact of PCV13 on pneumococcal disease and carriage of strains which move from person to person within the Navajo community. We specifically intend to find out if use of PCV13 has an effect on disease and carriage of the 6 additional strains in the vaccine and to find out if PCV13 will result in the emergence of new pneumococcal serotypes within the community, like PCV7 did. This information will allow us to design vaccine strategies to meet these new patterns of pneumococcal disease and stay at least one step ahead of the organism changes. It will also provide the evidence on which rational policies for PCV13 use among Navajo can be made. This has been essential information in past experiences of vaccine shortages, where Navajo communities were given priority for vaccine use. We also propose to explore the correlations between pneumococcal colonization and viral infection of the nasopharynx to establish if there is enhanced risk of pneumococcal colonization in the setting of viral co-infection and if that enhances the risk of developing disease. To achieve the overall objectives we propose pulling together three types of information (1) effect of PCV13 on nasopharyngeal colonization with pneumococcus and viral pathogens (2) effect of PCV13 on disease and (3) use of PCV13 in the community.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 6628
• Est. completion date: April 2012
• Est. primary completion date: April 2012
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 7 Months and older

Eligibility

Inclusion Criteria:

• American Indian children and their families (i.e. people of all ages) who live in the Whiteriver, Fort Defiance, Chinle, Gallup, Shiprock Service Units are eligible to participate in the carriage portion of the study.

Exclusion Criteria:

• Anyone with a congenital anomaly of the nasopharynx would not be eligible to participate in the carriage portion of the study

Study Design

Observational Model: Family-Based, Time Perspective: Cross-Sectional

Related Conditions & MeSH terms

• Invasive Pneumococcal Disease
• Pneumococcal Nasopharyngeal Colonization

Locations

Country	Name	City	State
United States	Navajo reservation	Gallup	New Mexico
United States	White Mountain Apache reservation	Whiteriver	Arizona

Sponsors (4)

Lead Sponsor	Collaborator
Johns Hopkins Bloomberg School of Public Health	Centers for Disease Control and Prevention, National Institutes of Health (NIH), Pfizer

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Nasopharyngeal carriage or Invasive Pneumococcal Disease caused by a PCV13 serotype		Before PCV13 introduction and after 1 and 2 years of PCV13 use	No